# Pfizer Inc. (PFE)

> Actualizado: 2026-01-27
> Status: EVALUANDO (pendiente /decide)
> Confianza: MEDIA-ALTA

## TL;DR

Pfizer es big pharma US #5 por market cap ($146B), atravesando transici√≥n post-COVID dif√≠cil con patent cliff 2026-28 ($17-18B revenue loss). Cotiza P/E 14.8x (22% bajo hist√≥rico) con **dividend yield 6.84%** (EXTREMO para big pharma). Forward P/E 8.81x = barato prospectivo. Management betting on obesity pipeline (Metsera GLP-1) + oncology ADCs para reponer revenue loss. Moat pharma (patents, scale, manufacturing) DURABLE pero erosionando por LOE. Balance s√≥lido Debt/Eq 0.67x, FCF $12.4B robusto. Margen seguridad 25-35% si pipeline ejecuta medianamente. **Yield 6.84% cushion defensa contra downside mientras se resuelve transici√≥n.** MENOS execution risk que Sanofi, M√ÅS defensivo que biotech. Decisi√≥n: Validar con Investment Committee.

---

## El Negocio

### Modelo

Pfizer es **big pharma diversificado** operando desarrollo, manufactura y comercializaci√≥n de medicamentos + vacunas globalmente.

**Estructura negocio (post-COVID transition 2026):**

1. **Biopharma** (85-90% revenue):
   - **Oncolog√≠a**: Ibrance (breast cancer), Xtandi (prostate - compartido), ADCs en pipeline
   - **Immunology/Inflammation**: Xeljanz, pipeline
   - **Cardio/Anticoagulantes**: Eliquis ($6-7B/a√±o, TOP drug), Vyndaqel
   - **Rare Disease**: Vyndaqel (cardiomyopathy), orphan drugs
   - **Internal Medicine**: Diversos

2. **Vacunas** (10-15% revenue):
   - **Prevnar 20** (pneumococcal, sucesor Prevnar 13): $5-6B/a√±o
   - **Comirnaty** (mRNA COVID): $1.5B 2026E (vs peak $36B 2022)
   - **RSV vaccine**: Lanzamiento reciente
   - **Pipeline vacunas**: mRNA flu, combination vaccines

3. **COVID products declining** (residual):
   - Comirnaty + Paxlovid: $1.5B 2026E (vs $56B combined 2022)
   - Transici√≥n completa esperada 2027

### Scale & Geography

- **Revenue 2026E**: $59.5-62.5B (guidance)
- **Market cap**: $146B (vs Eli Lilly $715B, J&J $401B, Merck $260B)
- **Empleados**: ~80,000
- **Geograf√≠a**: Global (US ~40%, EU ~30%, Emerging ~20%, Otros ~10%)

### Modelo Econ√≥mico

**Revenue drivers:**
- Branded drugs (patents protect): High margin (70-80% gross margin)
- Post-LOE: Revenue loss BUT cost structure ajustada
- R&D: ~15% revenue ($9-10B/a√±o)
- Manufacturing scale: Cost advantage vs biotech

**Transici√≥n 2024-2028:**
- **Peak COVID (2022)**: $100B revenue (anomal√≠a)
- **2025E**: $62B revenue (-‚Ç¨38B desde peak, transici√≥n casi completa)
- **2026E**: $59.5-62.5B (decline continuado por LOE)
- **2027+**: Crecimiento si pipeline ejecuta (obesity, oncology)

---

## Moat

**Rating: WIDE (Morningstar confirma) pero EROSIONANDO temporalmente**

### 1. Patents (Core Moat)

**Fortalezas:**
- Portfolio 108 drugs en pipeline (47 Phase 1, 28 Phase 2, 30 Phase 3, 3 approval)
- Patent exclusivity = pricing power extremo (Eliquis genera $6-7B/a√±o)
- Regulatory barriers FDA = competencia limitada

**Erosi√≥n temporal:**
- **Patent cliff 2026-28**: $17-18B revenue loss
  - Prevnar 13 US patents expire 2026 (mitigado por Prevnar 20)
  - Eliquis Medicare negotiation 2026 (price cut)
  - Ibrance, Xtandi LOE 2027
- Post-cliff: Moat se RECONSTRUYE si pipeline ejecuta

**Durabilidad:**
- Pharma moat es CICLICO: Patents expire ‚Üí nuevos drugs reponen
- Pfizer hist√≥ricamente repone ~70% patents loss (no 100%)
- Si obesity pipeline funciona ‚Üí moat se restaura 2028-30

### 2. Scale & Manufacturing

**Fortalezas:**
- Manufacturing capacity global: Pocos pueden producir billions dosis vacunas
- mRNA platform post-COVID: Capability √∫nica (Pfizer + BioNTech)
- R&D $9-10B/a√±o: Solo top 5 pharma pueden igualar
- Distribution network: Alcance 150+ pa√≠ses

**Vs biotech:** Pfizer puede llevar drug desde discovery ‚Üí comercializaci√≥n globalmente. Biotech NO (necesitan partner).

**Vs generics:** Pfizer post-LOE shift producci√≥n a bajo costo, mantiene margin decente.

### 3. Brand & Trust (Moderate Moat)

**Fortalezas:**
- Brand recognition doctors/hospitals
- Regulatory track record (FDA relationships, clinical trials expertise)
- COVID vacuna raised profile (controversial pero awareness ‚Üë)

**Pero:**
- Pharma switching costs BAJOS (doctors cambian si drug mejor/m√°s barato)
- Brand menos importante que patents

### Durabilidad del Moat: 10+ a√±os

**Pr√≥ximos 5 a√±os (2026-30):** Moat D√âBIL por patent cliff. Pipeline DEBE ejecutar o moat erosiona permanentemente.

**Post-2030:** Si obesity (Metsera) funciona + oncology ADCs ejecutan ‚Üí moat wide se restaura. Si falla ‚Üí moat narrow permanente.

**Conclusi√≥n:** Wide moat hist√≥rico, pero en transici√≥n cr√≠tica. NO es moat permanente tipo Mastercard, es c√≠clico pharma.

---

## Financials

### M√©tricas Clave (2026)

| M√©trica | Valor | vs Hist√≥rico 5Y | vs Peers Pharma | Comentario |
|---------|-------|-----------------|-----------------|------------|
| **Precio** | $25.65 | -50% desde COVID peak $61 | Bajo | COVID inflaci√≥n, ahora normalizando |
| **Market Cap** | $146B | Medio | Lilly $715B, J&J $401B, Merck $260B | #5 big pharma |
| **P/E (TTM)** | **14.82x** | **-22% vs hist√≥rico** | J&J ~17x, Merck ~16x | BARATO |
| **P/E Forward** | **8.81x** | Muy bajo | Sector ~15x | **EXTREMADAMENTE BARATO** si guidance realista |
| **EV/EBITDA** | ~10x (est) | Bajo | Sector 12-15x | Fair-cheap |
| **Dividend Yield** | **6.84%** | Alto hist√≥ricamente | J&J 3.0%, Merck 3.4%, Sanofi 4.85% | **M√ÅS ALTO BIG PHARMA** |
| **Payout Ratio** | ~100% | Alto | Sector 50-70% | Sostenible si earnings estables |
| **Debt/Equity** | **0.67x** | Bajo (mejor√≥ de 0.94x 5Y ago) | Sector 0.5-1.5x | **S√ìLIDO** |
| **ROE** | 10.60% | Bajo (hist√≥rico 15-20%) | Sector 15-25% | Deprimido por COVID transition |
| **ROIC** | 7.04% | Bajo | Sector 10-15% | Idem, transitorio |

### Rentabilidad y Balance

| M√©trica | Valor 2025 | Benchmark | Comentario |
|---------|-----------|-----------|------------|
| **Revenue** | $62B (2025E) | Peak COVID $100B | Transici√≥n casi completa |
| **Net Income** | $9.83B (TTM) | COVID peak $31B 2022 | Normalizado |
| **EPS** | $1.73 (TTM) | $5.50 COVID peak | Normalizado |
| **Gross Margin** | ~70-75% (est) | Pharma t√≠pico 70-80% | S√≥lido |
| **Operating Margin** | ~20-25% (est) | Pharma t√≠pico 20-30% | Decent post-COVID |
| **Total Assets** | $206B | Estable | - |
| **Total Debt** | $61.9B | Manageable | - |
| **Net Debt** | $60.2B | - | Debt/EBITDA ~3x (safe <4x) |
| **Equity** | $93.1B | S√≥lido | - |

### Cash Flow

| M√©trica | 2025 TTM | Tendencia | Calidad |
|---------|----------|-----------|---------|
| **Operating CF** | ~$15-18B (est) | Declining desde COVID | Alto |
| **FCF** | **$12.4B** (Q2 2025) | Declining but STRONG | Robusto |
| **Capex** | ~$3-4B/a√±o | Estable | Pharma t√≠pico |
| **Dividendo Paid** | $9.8B/a√±o ($1.72/share) | Sostenible | Cubierto por FCF |

**FCF Quality:** ALTA. FCF $12.4B cubre dividendo $9.8B + buybacks opcionales.

### Guidance 2026

| M√©trica | Guidance 2026 | vs 2025 | Comentario |
|---------|---------------|---------|------------|
| **Revenue** | $59.5-62.5B | -4% a flat | Decline por COVID -$1.5B + LOE -$1.5B |
| **Adj EPS** | $2.80-3.00 | Flat-slightly up | Crecimiento operacional 4% ex-COVID/LOE |
| **Operational Growth (ex-COVID/LOE)** | ~4% | Modest | Base business s√≥lido |

**Pensamiento Cr√≠tico sobre Guidance:**
- Management siempre optimista ‚Üí Descuento 10-20%
- PERO: Guidance 2025 fue conservative, hitting targets ‚Üí credibilidad ALTA
- COVID decline $1.5B es FACT (contratos finalizando)
- LOE $1.5B es FACT (patents expiran)
- Operational growth 4% parece REALISTA (no fantasy 10%+)

**Conclusi√≥n:** Guidance 2026 conservador y cre√≠ble. EPS $2.80-3.00 alcanzable.

---

## Valoraci√≥n

### Pensamiento Cr√≠tico Pre-Valuaci√≥n

**¬øPor qu√© P/E 14.8x (forward 8.81x) barato?**

Mercado pricing:
1. **Patent cliff 2026-28** ($17-18B revenue loss = real)
2. **Obesity pipeline risk** (Metsera GLP-1 late to party, Lilly/Novo dominating)
3. **Post-COVID overhang** (investors burned, perdieron 50% desde peak)
4. **Pipeline execution doubt** (Pfizer perdi√≥ GLP-1 race, oncology pipeline vs Merck/Lilly?)

**¬øEs pesimismo EXCESIVO?**
- Patent cliff es KNOWN ($17-18B), ya en guidance ‚Üí priced in
- Obesity: Late pero ultra-long-acting GLP-1 diferenciado (dosing 1x/month vs weekly)
- Yield 6.84% cushion = downside protegido si tesis toma tiempo
- FCF $12B s√≥lido ‚Üí no distress, solo transition

**¬øGuidance $2.80-3.00 EPS realista?**
- Management conservative track record 2024-25 ‚Üí s√≠
- Operational growth 4% ex-COVID/LOE razonable
- Uso EPS $2.90 base (midpoint)

### M√©todo 1: P/E Comparativo

**P/E actual:** 14.82x
**P/E forward:** 8.81x
**P/E pharma sector:** 15-18x t√≠pico

**Escenario base P/E 12x** (descuento 20% por transition risk):
- EPS 2026 $2.90 √ó 12 = **$34.80/share**

**Upside:** $34.80 vs $25.65 actual = **+36%**

### M√©todo 2: P/E Re-rating Post-Transition

**Si pipeline ejecuta 2027-28** (obesity Phase 3 positivo, oncology readouts buenos):
- P/E re-rates a 15x (sector average)
- EPS 2027E $3.20 (crecimiento post-LOE) √ó 15 = **$48.00/share**

**Upside:** +87% (long-term si todo sale bien)

### M√©todo 3: Dividend Yield Compression

**Yield actual:** 6.84%
**Yield pharma t√≠pico:** 3-4%

Si yield comprime a 5% (conservative, sigue alto):
- Dividendo $1.72 / 5% = **$34.40/share**

**Upside:** +34%

### M√©todo 4: Analistas Consensus

**Target consensus:** $30-32 (estimado, var√≠a por fuente)

**Upside:** +17-25% (conservative)

### Escenarios Valoraci√≥n

| Escenario | Asunciones | Valor/Share | vs $25.65 | Upside | Probabilidad |
|-----------|------------|-------------|-----------|--------|--------------|
| **Pesimista** | Pipeline falla, LOE worse, P/E 10x, EPS $2.50 | $25.00 | -3% | - | 20% |
| **Base** | Pipeline mediano, LOE manageable, P/E 12x, EPS $2.90 | **$34.80** | **+36%** | +36% | 60% |
| **Optimista** | Obesity √©xito, P/E 15x, EPS 2027 $3.20 | $48.00 | +87% | +87% | 20% |

**Precio actual:** $25.65

**Valor intr√≠nseco base:** $32-35

**Margen de seguridad:** **25-36%** (usando $34.80 base)

**Target entrada:** $25-27 (actual range OK)

---

## Riesgos

### 1. Patent Cliff Execution Failure (Probabilidad: 30-40%, Impacto: ALTO)

**Riesgo:** Pipeline NO repone $17-18B revenue loss 2026-28. Obesity falla Phase 3, oncology readouts negativos.

**Impacto:**
- Revenue decline contin√∫a post-2028
- EPS $2.50 vs $2.90 base ‚Üí valuaci√≥n cae a P/E 10x = $25 (downside -3%)
- Dividendo recorte posible (aunque FCF $12B cubre $9.8B dividendo)

**Mitigaci√≥n:**
- Portfolio 108 drugs pipeline diversificado (no todo o nada)
- Obesity = upside, NO critical para thesis (base case NO asume obesity √©xito)
- FCF $12B robusto ‚Üí puede sostener dividendo incluso si pipeline slow

**Probabilidad pipeline falla TOTALMENTE:** Baja (15-20%). Probabilidad falla PARCIALMENTE (solo repone 50-70% LOE): Media (30-40%).

### 2. Obesity Pipeline Late-to-Market (Probabilidad: 50-60%, Impacto: MEDIO)

**Riesgo:** Metsera GLP-1 launches 2028, pero Lilly/Novo ya dominan mercado con versiones mejores (orales, dual agonists).

**Impacto:**
- Obesity upside NO materializa ($5-10B potential revenue perdido)
- Pfizer queda #3-4 player en obesity (late entrant penalty)
- Stock NO re-rates a P/E 15x, queda en P/E 12-13x

**Mitigaci√≥n:**
- Ultra-long-acting diferenciado (1x/month dosing) = nicho adherence
- Obesity market $100B+ 2030, room para 3-4 players
- Base case NO requiere obesity √©xito para upside 25-35%

**Conclusi√≥n:** Obesity es OPCI√ìN, no thesis core. Si falla ‚Üí upside 25-35%. Si funciona ‚Üí upside 50-80%.

### 3. Dividend Cut Risk (Probabilidad: 15-20%, Impacto: ALTO)

**Riesgo:** Payout ratio 100% insostenible si EPS decline contin√∫a. Management recorta dividendo para invertir pipeline.

**Impacto:**
- Yield investors salen ‚Üí stock cae 10-20%
- Yield comprime de 6.84% a 4-5% ‚Üí price falls to $20-22
- Thesis invalidated (yield cushion desaparece)

**Mitigaci√≥n:**
- FCF $12.4B cubre dividendo $9.8B holgadamente
- Pfizer 17 a√±os consecutive dividend increases ‚Üí track record
- Management prioritiza dividendo (investor base retirees)

**Probabilidad cut:** Baja (15-20%) si FCF mantiene >$10B.

### 4. Regulatory/Pricing Pressure (Probabilidad: 40-50%, Impacto: MEDIO)

**Riesgo:** Medicare negotiation expande a m√°s drugs. Eliquis ya en lista 2026, m√°s drugs a√±adidos 2027-28.

**Impacto:**
- Price cuts 25-60% en negotiated drugs
- Revenue impact -$1-2B adicional beyond guidance
- Margin compression 5-10%

**Mitigaci√≥n:**
- Pharma sector-wide issue (Merck, J&J tambi√©n afectados)
- Pfizer diversificado geogr√°ficamente (US solo 40% revenue)
- Pricing pressure YA en guidance 2026 (Eliquis negotiation)

**Conclusi√≥n:** Riesgo REAL pero manageable, ya partially priced.

### 5. Debt Level y Interest Expense (Probabilidad: 20-25%, Impacto: BAJO)

**Riesgo:** Debt $62B con tipos Fed 3.5-3.75%. Interest expense ~$2-2.5B/a√±o.

**Impacto:**
- Si tipos suben a 5% ‚Üí interest expense +$500M-1B
- FCF presi√≥n (de $12B a $11B)
- Rating downgrade risk

**Mitigaci√≥n:**
- Debt/Eq 0.67x es BAJO para pharma (s√≥lido)
- Debt/EBITDA ~3x (safe, <4x threshold)
- Fed unlikely sube tipos (consensus flat 2026)

**Conclusi√≥n:** Riesgo BAJO.

### 6. Invalidaci√≥n de Thesis

**La thesis se invalida si:**
1. **Dividendo recortado** (yield cushion desaparece)
2. **EPS 2026 <$2.50** (miss guidance significativo)
3. **Obesity Phase 3 falla + oncology readouts negativos** (pipeline colapso total)
4. **FCF <$8B** (insostenible pagar dividendo)
5. **Debt/Equity >1.2x** (leverage peligroso)

**M√©tricas monitorear:**
- EPS trimestral (mantener track $2.80-3.00 guidance)
- Dividendo announcements (mantener $1.72+)
- Pipeline readouts (obesity Phase 3, oncology ADCs)
- FCF (mantener >$10B)

---

## Catalizadores

### Corto Plazo (3-6 meses)

1. **Feb 3, 2026 earnings** (3 d√≠as) ‚Üí Validar guidance 2026, pipeline update
2. **Dividendo Q1 2026 confirmation** ‚Üí Yield 6.84% sostenible
3. **Metsera Phase 3 enrollment complete** ‚Üí Demuestra commitment obesity
4. **Oncology readouts Q1-Q2** ‚Üí Padcev, ADCs data

### Medio Plazo (6-18 meses)

1. **Obesity Phase 3 data readout** (2027) ‚Üí Make-or-break para re-rating
2. **Eliquis Medicare pricing finalized** ‚Üí Remove uncertainty
3. **LOE impact tracking** ‚Üí Validar guidance -$1.5B manageable
4. **Pipeline additions** ‚Üí M&A peque√±o probable (Pfizer tiene cash)

### Largo Plazo (2+ a√±os)

1. **Metsera approval 2028** ‚Üí Obesity market entry, revenue growth
2. **Post-LOE stabilization** ‚Üí EPS growth resume 2027-28
3. **Dividend growth resumes** ‚Üí De $1.72 a $1.85-2.00 (yield on cost >7%)
4. **P/E re-rating 14.8x ‚Üí 15-16x** ‚Üí Sector average, transition complete

---

## Contexto Macro (de world view 2026-01-26)

### Favorable

- **US growth 2%**: No recesi√≥n ‚Üí demanda healthcare estable
- **Fed tipos estables 3.5-3.75%**: No m√°s subidas ‚Üí pharma valuations no comprimen m√°s
- **Aging demographics**: US/EU population envejeciendo ‚Üí m√°s demanda drugs

### Neutral

- **Inflaci√≥n 3%**: Pricing power pharma compensa
- **Dollar strength**: Pfizer 40% US, 60% international ‚Üí FX neutral

### Desfavorable

- **Medicare negotiation**: Political pressure pricing ‚Üí margin compression
- **No tailwinds tipos bajando**: Pharma no re-rates por tipos (como utilities)

**Conclusi√≥n macro:** Entorno NEUTRAL para pharma. No vientos favor/contra significativos.

---

## Comparaci√≥n vs Alternativas

### Pfizer vs Sanofi (Watchlist)

| | **Pfizer** | **Sanofi** |
|-|------------|------------|
| **P/E** | 14.8x | 9.9x (Sanofi M√ÅS barata) |
| **Forward P/E** | **8.81x** | ~10x |
| **Yield** | **6.84%** | 4.85% (Pfizer +40% yield) |
| **Moat** | Wide pero erosionando | Narrow (Dupixent temporal) |
| **Pipeline risk** | Medio (diversificado) | **ALTO** (12 blockbusters o bust) |
| **Geography** | US 40%, Global 60% | EU 100% |
| **Execution risk** | **BAJO** (track record, scale) | ALTO (pipeline unproven) |
| **Margen seguridad** | 25-36% | 20-25% (Sanofi watchlist) |

**Preferencia:** **Pfizer** para defensive value (yield 6.84% cushion, MENOS execution risk). **Sanofi** para aggressive value (m√°s barata pero requiere pipeline hits).

### Pfizer vs Merck

- **Merck**: P/E 16x, yield 3.4%, Keytruda cliff 2028
- **Pfizer**: P/E 14.8x, yield 6.84%, multiple cliffs 2026-28

**Preferencia:** **Pfizer** m√°s barata (P/E 14.8x vs 16x) + yield 2x higher (6.84% vs 3.4%).

### Pfizer vs J&J

- **J&J**: P/E 17x, yield 3.0%, diversified (pharma + medtech)
- **Pfizer**: P/E 14.8x, yield 6.84%, pure pharma

**Preferencia:** **Pfizer** valuaci√≥n (14.8x vs 17x) + yield (6.84% vs 3.0%). J&J mejor quality (dividend king 54 a√±os) pero pagar 15% premium sin yield.

### Pfizer vs Enel (Portfolio context)

**Enel** (comprado ‚Ç¨600):
- P/E 9.6x, yield 5%, utilities defensive, riesgo LATAM
- Margen seguridad 21-35%

**Pfizer**:
- P/E 14.8x, yield 6.84%, pharma defensive, riesgo pipeline
- Margen seguridad 25-36%

**Comparaci√≥n:** Ambos defensive value, yield alto, riesgos reales. Pfizer M√ÅS barata prospectivamente (forward P/E 8.81x vs Enel 9.6x) + yield higher (6.84% vs 5%). **Portfolio fit:** A√±ade US exposure + pharma sector (vs Enel EU utilities).

---

## Decisi√≥n Preliminar

### Pendiente Investment Committee

**Checklist inicial:**
- [x] Thesis completa
- [x] Margen seguridad >25%: **25-36%** ‚úÖ
- [x] Moat identificado: Wide pharma (patents, scale, manufacturing)
- [x] Riesgos conocidos: Patent cliff, pipeline execution, dividend sustainability
- [x] Macro compatible: US healthcare neutral, no headwinds espec√≠ficos

**Problemas potenciales:**
1. Forward P/E 8.81x requiere CONFIAR guidance $2.80-3.00 (riesgo miss)
2. Yield 6.84% payout 100% = riesgo dividend cut si EPS decline
3. Pipeline execution risk REAL (obesity late, oncology unproven)

**Pero:**
- Yield 6.84% cushion ENORME = downside protegido
- P/E 14.8x (TTM) barato incluso sin forward optimism
- FCF $12.4B s√≥lido cubre dividendo + margen
- MENOS execution risk que Sanofi (diversificado, scale)

### Recomendaci√≥n Preliminar: **COMPRAR CON CAUTELA**

**Razones PARA:**
1. **Yield 6.84%** = highest big pharma, cushion defensa downside
2. **P/E 14.8x** (forward 8.81x) = barato vs sector 15-18x
3. **Margen seguridad 25-36%** cumple >25% requerido
4. **FCF $12.4B** robusto, dividendo sostenible
5. **MENOS execution risk** que Sanofi (escala, track record)
6. **US exposure** diversifica portfolio (tengo UK, EU, LATAM)
7. **Defensive pharma** fit portfolio gap 35-40% defensive

**Razones CONTRA (Cautelas):**
1. **Patent cliff 2026-28** real ($17-18B revenue loss)
2. **Pipeline execution risk** (obesity late, oncology unproven)
3. **Payout ratio 100%** = riesgo dividend cut si EPS decline
4. **Post-COVID overhang** = investor sentiment negativo
5. **Yield 6.84% parece "too good to be true"** ‚Üí validar sostenibilidad

### Sizing & Entrada (Preliminar)

- **Precio entrada**: $24-27 (actual $25.65 OK)
- **Sizing**: **5-6% portfolio** (‚Ç¨500-600 de ‚Ç¨6,700 cash)
  - Standard Defensive: 5% base
  - +0-1% por yield 6.84% cushion
- **Horizonte**: 3-5 a√±os (transition complete 2028-29)
- **Upside target**: +25-35% base ($32-35), +50-80% optimista si pipeline hits

**Rationale sizing:**
- Menor que Enel 6% (Pfizer m√°s execution risk)
- Similar a Sanofi (si Sanofi se comprara, sizing 5%)
- Defensive pharma para llenar gap 35-40%

### Monitoreo

**Inmediato:**
- Feb 3, 2026 earnings (3 d√≠as)
- Guidance 2026 validation
- Pipeline update

**Trimestral:**
- EPS tracking (mantener $2.80-3.00 track)
- Dividendo announcements
- Pipeline readouts (obesity, oncology)
- FCF (mantener >$10B)

**Anual:**
- Patent cliff impact real vs guidance
- Obesity Phase 3 progress
- P/E re-rating (14.8x ‚Üí 15-16x?)

### Venta (cuando)

**Vender si:**
1. Alcanza $34-36 (full valuation base, upside 25-35% logrado)
2. Dividendo recortado (thesis invalidated)
3. Pipeline colapso (obesity falla + oncology negativo)
4. EPS <$2.50 sustained (guidance miss significativo)
5. FCF <$8B (insostenible)

**Hold si:**
- Volatilidad precio por macro (thesis intacta)
- Pipeline delays menores (esperado pharma)
- LOE impact dentro guidance (manageable)

**A√±adir si:**
- Precio cae a $22-24 Y pipeline intact ‚Üí margen >40%
- Obesity Phase 3 positivo ‚Üí re-rate opportunity

---

## Clasificaci√≥n Portfolio (V2.0)

**Tipo:** DEFENSIVE

**Raz√≥n clasificaci√≥n:**
- Pharma = defensive (healthcare demand recession-resistant)
- Dividendo 6.84% sostenible (payout cubierto por FCF)
- Drawdown esperado: -20-25% en crisis (vs -35-45% cyclicals)
- Beta pharma ~0.7-0.8

**Sizing recomendado:**
- Tipo: Standard Defensive
- Base sizing: 5%
- Ajuste: +0-1% por yield 6.84% cushion extraordinario
- **Sizing final: 5-6%** = ‚Ç¨500-600

**Balance portfolio post-compra (sizing 5% = ‚Ç¨500):**
- Defensive actual: 6% (Enel) ‚Üí post: 11% (target 35-40%) - sigue corto
- Cyclical actual: 27% ‚Üí post: 27% (target 45-50%)
- Total invested: 33% ‚Üí 38%
- Cash: 67% ‚Üí 62%
- Posiciones: 3 ‚Üí 4

**Check:** ‚úÖ Dentro rangos, construyendo gradualmente

---

## Seguimiento

**Pr√≥ximo earnings:** Feb 3, 2026 (3 D√çAS)

**M√©tricas clave monitorear:**
1. **EPS Q4 2025 y guidance 2026** - Validar $2.80-3.00
2. **Revenue 2026 guidance** - Confirmar $59.5-62.5B
3. **Dividendo Q1 2026** - Mantener $0.43/quarter ($1.72/a√±o)
4. **Pipeline update** - Metsera Phase 3, oncology readouts
5. **FCF Q4 2025** - Mantener >$12B anualizado
6. **LOE impact commentary** - Eliquis, Prevnar 13, tracking

**Revisar thesis si:**
1. ‚ùå **Dividendo recortado** (yield cushion desaparece)
2. ‚ùå **EPS 2026 <$2.50** (miss guidance >15%)
3. ‚ùå **Pipeline colapso** (obesity + oncology negativo)
4. ‚ùå **FCF <$8B** (insostenible dividendo)
5. ‚úÖ **Precio cae a $22-24** (a√±adir si thesis intacta)
6. ‚úÖ **Obesity Phase 3 positivo** (re-valorar upside)

---

## Autocr√≠tica del An√°lisis

**Asunciones validadas:**
- ‚úÖ P/E 14.8x, forward 8.81x confirmado m√∫ltiples fuentes
- ‚úÖ Yield 6.84% confirmado (Yahoo, MacroTrends)
- ‚úÖ Guidance 2026 $59.5-62.5B, EPS $2.80-3.00 oficial Pfizer
- ‚úÖ Patent cliff $17-18B confirmado (Prevnar 13, Eliquis, Ibrance, Xtandi)

**Sesgos detectados:**
- ‚ö†Ô∏è **Sesgo yield:** 6.84% yield muy atractivo, riesgo sesgo confirmaci√≥n buscando razones comprar
- ‚ö†Ô∏è **Comparaci√≥n Sanofi:** Usando Sanofi como benchmark puede inflar Pfizer (Pfizer scale >Sanofi)
- ‚ö†Ô∏è **Forward P/E 8.81x:** Requiere CONFIAR guidance, riesgo optimism

**Evidencia ignorada o minimizada:**
- üîç **Payout ratio 100%:** Se√±al warning, minimizado por "FCF covers" (PERO margen error bajo)
- üîç **Investor sentiment negativo:** -50% desde COVID peak, burned investors may take years return
- üîç **Obesity late-to-market:** Lilly/Novo dominating, Pfizer dif√≠cil catch-up (minimizado como "opci√≥n")

**Alternativas consideradas:**
- ‚úÖ Merck: P/E 16x, yield 3.4% ‚Üí Pfizer mejor (14.8x + 6.84% yield)
- ‚úÖ J&J: P/E 17x, yield 3.0% ‚Üí Pfizer better value
- ‚úÖ Sanofi: P/E 9.9x, yield 4.85% ‚Üí Sanofi cheaper BUT riskier
- ‚ùå NO consider√©: Lilly (obesity leader pero P/E 40x+ = caro)

**Decisi√≥n post-autocr√≠tica:**
- Thesis COMPRAR sigue siendo correcta
- PERO: Reconocer yield 6.84% cushion NO es "free lunch" ‚Üí market pricing patent cliff + pipeline risk
- Ajusto sizing: 5% (conservative) vs 6% (agressive), dada payout 100% y pipeline execution risk
- CR√çTICO: Validar earnings Feb 3 ANTES de comprar definitivo (3 d√≠as)

---

## Contexto Macro Aplicado

**Entorno pharma US 2026 (de world view 2026-01-26):**
- ‚û°Ô∏è US growth 2%, no recesi√≥n ‚Üí demanda healthcare estable (neutral)
- ‚û°Ô∏è Fed tipos 3.5-3.75% estables ‚Üí pharma valuations no comprimen m√°s (neutral)
- ‚¨áÔ∏è Medicare negotiation ‚Üí pricing pressure (desfavorable, pero ya en guidance)
- ‚úÖ Aging demographics US/EU ‚Üí tailwind largo plazo (+)

**Implicaci√≥n:** Macro NO tailwind fuerte, pero tampoco headwind. Pharma defensive aguanta. Pfizer valuation barata por company-specific (patent cliff) NO macro.

---

## Fuentes

**Financials & Valuation:**
- [Yahoo Finance: Pfizer Key Statistics](https://finance.yahoo.com/quote/PFE/key-statistics/)
- [Stock Analysis: Pfizer Statistics](https://stockanalysis.com/stocks/pfe/statistics/)
- [Morningstar: Pfizer Quote](https://www.morningstar.com/stocks/xnys/pfe/quote)
- [MacroTrends: Pfizer Dividend History](https://www.macrotrends.net/stocks/charts/PFE/pfizer/dividend-yield-history)
- [Full Ratio: Pfizer P/E Analysis](https://fullratio.com/stocks/nyse-pfe/pe-ratio)

**Earnings & Guidance:**
- [Pfizer: 2025 EPS Guidance & 2026 Guidance](https://www.pfizer.com/news/press-release/press-release-detail/pfizer-reaffirms-full-year-2025-eps-guidance-and-provides)
- [Pfizer Insights: 2026 Guidance Takeaways](https://insights.pfizer.com/2026-guidance-key-takeaways)
- [Investing.com: Pfizer 2026 Revenue Projections](https://www.investing.com/news/company-news/pfizer-projects-2026-revenue-of-595625-billion-adjusts-2025-outlook-93CH-4410258)
- [CNBC: Pfizer 2026 Guidance Metsera Seagen](https://www.cnbc.com/2025/12/16/pfizer-2026-guidance-metsera-seagen-deals.html)

**Pipeline & Moat:**
- [SyneticX: Pfizer 2026 Competitive Outlook](https://www.syneticx.com/blog/pfizer.html)
- [Yahoo Finance: Pfizer Wide Moat](https://finance.yahoo.com/news/patents-economies-scale-support-pfizers-095938450.html)
- [AInvest: Pfizer Patent Cliff Value Analysis](https://www.ainvest.com/news/pfizer-investor-patent-cliff-obesity-bet-2601/)
- [BioSpace: Pfizer Obesity Programs JPM26](https://www.biospace.com/business/jpm26-pfizer-fast-tracks-obesity-programs-in-race-against-patent-cliff)
- [Seeking Alpha: Pfizer Patent Cliff Debt](https://seekingalpha.com/article/4859104-pfizer-patent-cliff-rising-debt-and-the-fight-to-stay-a-buy)

**Balance Sheet & Cash Flow:**
- [MarketBeat: Pfizer Financials 2026](https://www.marketbeat.com/stocks/NYSE/PFE/financials/)
- [Yahoo Finance: Pfizer Balance Sheet](https://finance.yahoo.com/quote/PFE/balance-sheet/)
- [MacroTrends: Pfizer Cash Flow](https://www.macrotrends.net/stocks/charts/PFE/pfizer/cash-flow-statement)
- [Simply Wall St: Pfizer Health Metrics](https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-pfe/pfizer/health)

**Peer Comparison:**
- [Motley Fool: Pfizer vs Merck 2026](https://www.fool.com/investing/2025/12/19/better-buy-in-2026-pfizer-or-merck/)
- [Nasdaq: Pfizer vs Merck Better Buy](https://www.nasdaq.com/articles/better-buy-2026-pfizer-or-merck)
- [AlphaSense: Largest Pharma by Market Cap 2026](https://www.alpha-sense.com/largest-pharmaceutical-companies-by-market-cap/)
